Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01532310 · ClinicalTrials.gov registry record
Belimumab (BENLYSTA®) Pregnancy Registry
A clinical trial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- 77
- Enrollment target
NCT01532310 is a clinical trial that has completed, run by GlaxoSmithKline. The registered enrollment target is 77 participants.
The verdict
NCT01532310 has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- 77 participants
- Enrollment target
Study Summary
This global Belimumab Pregnancy Registry will collect prospective data on pregnancies and pregnancy outcomes on a voluntary basis in women with systemic lupus erythematosus (SLE) who have received commercially supplied belimumab within the 4 months prior to and/or during pregnancy. The registry will also evaluate outcomes of infants born to mothers who were exposed to belimumab within the 4 months prior to and/or during pregnancy. This registry will add to the current clinical experience with belimumab and will complement reproductive data from animal toxicology studies. It will also assist clinicians in weighing the potential risks against the benefits of treatment for individual patients with SLE. GlaxoSmithKline (GSK) will sponsor the Belimumab Pregnancy Registry in countries where it holds Marketing Authorization.
Interventions
- DRUG belimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2012-07-16 |
| Est. Completion | 2022-11-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01532310
The ClinicalTrials.gov registry entry for NCT01532310 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which belimumab is the first listed.
NCT01532310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01532310 about?
NCT01532310 is a clinical study titled "Belimumab (BENLYSTA®) Pregnancy Registry". This global Belimumab Pregnancy Registry will collect prospective data on pregnancies and pregnancy outcomes on a voluntary basis in women with systemic lupus erythematosus (SLE) who have received commercially supplied belimumab within the 4 months prior to and/or during pregnancy. The registry will...
What is the current status of trial NCT01532310?
This trial is currently completed. The enrollment target is 77 participants. The study started on 2012-07-16. Estimated completion is 2022-11-11.
What interventions are being tested in trial NCT01532310?
The interventions under investigation include: belimumab (DRUG).
Who is sponsoring clinical trial NCT01532310?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.